P1097 is a Phase 0, multi-center washout pharmacokinetic trial of raltegravir in infants born to HIV-infected pregnant women. The study is designed to determine the washout pharmacokinetics and safety of in utero/intrapartum exposure following the infants for up to 20 weeks after birth.

Loading study documents...

Loading study sites...

Loading study protocol team...

Loading study press...

Loading study publications/presentations...